569-77-7
569-77-7 結(jié)構(gòu)式
基本信息
紅陪酚
1,2,3,9-四羥基苯并[7]環(huán)庚烯-8-酮
1,2,3,9-四羥基-8-苯并[7]環(huán)庚烯酮
5H-苯并環(huán)庚烯-5-酮,2,3,4,6-四羥基-
2,3,4,6-四羥基-5H-苯并[A]環(huán)庚烯-5-酮
2,3,4,6-四羥基-5H-苯并[7]環(huán)庚烯-5-酮
MLS0007
NSC 35676
NSC 646653
AIDS138915
CHEBI:8647
AIDS-138915
AKOS 209-004
KBio1_001351
KBio2_000828
物理化學(xué)性質(zhì)
SKIN CONDITIONING
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/12/22 | HY-12136 | 紅陪酚 Purpurogallin | 569-77-7 | 1 mg | 228元 |
| 2025/12/22 | HY-12136 | 紅陪酚 Purpurogallin | 569-77-7 | 5mg | 500元 |
| 2025/12/22 | HY-12136 | 紅陪酚 Purpurogallin | 569-77-7 | 10mM * 1mLin DMSO | 552元 |
常見問題列表
IC50: 0.2 μM (xanthine oxidase)
Purpurogallin (50 or 100 μM; 7 or 25 hours; BV2 murine microglial cells) treatment attenuates the production of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) by suppressing their mRNA and protein expression in LPS-stimulated BV2 microglial cells.
Purpurogallin (100 μM; 75-120 minutes; BV2 murine microglial cells) exhibits anti-inflammatory properties by suppressing the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways in LPS-stimulated BV2 microglial cells.
RT-PCR
| Cell Line: | BV2 murine microglial cells |
| Concentration: | 50 or 100 μM |
| Incubation Time: | 7 or 25 hours |
| Result: | Attenuated the production of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) by suppressing their mRNA and protein expression. |
Western Blot Analysis
| Cell Line: | BV2 murine microglial cells |
| Concentration: | 100 μM |
| Incubation Time: | 75 minutes, 90 minutes, 120 minutes |
| Result: | Suppressed the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase signaling pathways. |
Purpurogallin (100-400?μg/kg; intraperitoneal injection; for 48 or 72 hours; male Sprague-Dawley rats) exerts its neuroinflammation effect through the dual effect of inhibiting IL-6 and TNF-α mRNA expression and reducing HMGB1 protein and mRNA expression.
| Animal Model: | Fifty-four male Sprague-Dawley rats (250-350?g) with subarachnoid hemorrhage (SAH) |
| Dosage: | 100?μg/kg, 200?μg/kg, 400?μg/kg |
| Administration: | Intraperitoneal injection; for 48 or 72 hours |
| Result: | Dose-dependently reduced HMGB1 protein expression. High dose reduced TNF-α and HMGB1 mRNA levels. |